Researchers and the pharmaceutical industry may use preclinical imaging to review the safety and efficacy of drug candidates for respiratory diseases such as pneumonia, lung cancer, asthma and chronic obstructive pulmonary disease, write Nicolau Beckmann and Sarah-Rebecca Herrmann. Imaging technology may also reduce, replace and refine animal studies, as well as inform in vivo analysis of the toxicological effects of compounds without the need for dissecting tissues, while "innovation in imaging technology has helped researchers to better understand the underlying causes of many lung disorders," the authors wrote.
Imaging may help evaluate new drugs for lung diseases
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.